Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 11/20 | 0.56 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.56 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 4/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 4/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4613887 | 0.82 | BRD4 (0.56) | BRD4CREBBPCRBNKMT2AACE | |
| SCHEMBL29704455 | 0.82 | BRD4 (0.56) | BRD4CREBBPCRBNKMT2AACE | |
| SCHEMBL19657830 | 0.82 | BRD4 (0.56) | BRD4CREBBPCRBNKMT2AACE | |
| SCHEMBL20612876 | 0.81 | BRD4 (0.54) | BRD4CREBBPCRBNKMT2AACE | |
| SCHEMBL3598102 | 0.81 | BRD4 (0.54) | BRD4CREBBPCRBNKMT2AACE | |
| SCHEMBL13383385 | 0.79 | BRD4 (0.53) | BRD4CREBBPCRBNKMT2AACE | |
| SCHEMBL20597216 | 0.78 | CDK5 (0.52) | BRD4CREBBPKMT2ACDK5CDK5R1 | |
| SCHEMBL30116170 | 0.78 | CDK5 (0.52) | BRD4CREBBPKMT2ACDK5CDK5R1 | |
| SCHEMBL3594621 | 0.76 | ACE (0.46) | BRD4CREBBPACEMMP13 | |
| SCHEMBL3600609 | 0.76 | ACE (0.40) | BRD4CREBBPACEMMP13CDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2128157-A1 | HETEROCYCLIDENE-N-(ARYL)ACETAMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016285-A1 | HETEROCYCLIDENE-N-(ARYL) ACETAMIDE DERIVATIVE | CCNY, CCND3, NSD3 | BRD4 706/4885CREBBP 2015/4885CRBN 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.